1. Buruli ulcer: management of Mycobacterium ulcerans disease: a manual for health care providers,2001
2. Global epidemiology of Buruli ulcer, 2010–2017, and analysis of 2014 WHO programmatic targets;Omansen;Emerg Infect Dis,2019
3. Rifampicin and clarithromycin (extended release) versus rifampicin and streptomycin for limited Buruli ulcer lesions: a randomised, open-label, non-inferiority phase 3 trial;Phillips;Lancet,2020
4. A pilot study of treatment of Buruli ulcer with rifampin and dapsone;Espey;Int J Infect Dis,2002
5. “Paradoxical” immune-mediated reactions to Mycobacterium ulcerans during antibiotic treatment: a result of treatment success, not failure;O’Brien;Med J Aust,2009